Endometrial hyperplasia screening: Difference between revisions
Jump to navigation
Jump to search
Badria Munir (talk | contribs) No edit summary |
Badria Munir (talk | contribs) No edit summary |
||
Line 7: | Line 7: | ||
==Screening== | ==Screening== | ||
* Women receiving unopposed estrogens need endometrial sampling once every 2 years (relative risk increases only after 2 years of estrogen use), particularly if endometrial hyperstimulation has been documented previously and has not been treated by short-term administration of progestins. <ref name="pmid1893367">{{cite journal |vauthors=Hakala T, Mecklin JP, Forss M, Järvinen H, Lehtovirta P |title=Endometrial carcinoma in the cancer family syndrome |journal=Cancer |volume=68 |issue=7 |pages=1656–9 |date=October 1991 |pmid=1893367 |doi= |url=}}</ref> | |||
* Also, if the informed, high-risk individual requests an endometrial evaluation before or during HRT or at any time during her periodic health examinations, she should not be deprived of an office-based investigative procedure to rule out endometrial pathology. | |||
* An endometrial evaluation also should be performed in women at high risk for endometrial carcinoma, such as women with history of Lynch II syndrome. | |||
Women receiving unopposed estrogens need endometrial sampling once every 2 years (relative risk increases only after 2 years of estrogen use), particularly if endometrial hyperstimulation has been documented previously and has not been treated by short-term administration of progestins. Also, if the informed, high-risk individual requests an endometrial evaluation before or during HRT or at any time during her periodic health examinations, she should not be deprived of an office-based investigative procedure to rule out endometrial pathology. An endometrial evaluation also should be performed in women at high risk for endometrial carcinoma, such as women with history of Lynch II syndrome. | |||
==References== | ==References== |
Revision as of 20:53, 25 February 2019
Endometrial hyperplasia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Endometrial hyperplasia screening On the Web |
American Roentgen Ray Society Images of Endometrial hyperplasia screening |
Risk calculators and risk factors for Endometrial hyperplasia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Badria Munir M.B.B.S.[2] , Soujanya Thummathati, MBBS [3]
Oveview
Routine screening for endometrial hyperplasia or endometrial carcinoma is not recommended.
Screening
- Women receiving unopposed estrogens need endometrial sampling once every 2 years (relative risk increases only after 2 years of estrogen use), particularly if endometrial hyperstimulation has been documented previously and has not been treated by short-term administration of progestins. [1]
- Also, if the informed, high-risk individual requests an endometrial evaluation before or during HRT or at any time during her periodic health examinations, she should not be deprived of an office-based investigative procedure to rule out endometrial pathology.
- An endometrial evaluation also should be performed in women at high risk for endometrial carcinoma, such as women with history of Lynch II syndrome.